Get the Stockscreener App
164.49
0.28%
-0.46
After Hours:
163.99
-0.50
-0.30%
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca Plc stock is traded at $164.49, with a volume of 5.06M.
It is down -0.28% in the last 24 hours and down -0.02% over the past month.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
See More
Previous Close:
$164.95
Open:
$163.4
24h Volume:
5.06M
Relative Volume:
1.74
Market Cap:
$255.11B
Revenue:
$60.48B
Net Income/Loss:
$10.40B
P/E Ratio:
49.40
EPS:
3.3297
Net Cash Flow:
$8.05B
1W Performance:
+4.61%
1M Performance:
-0.02%
6M Performance:
-19.45%
1Y Performance:
+104.28%
1-Day Range:
$161.47
$165.57
1-Week Range:
$154.53
$165.91
52-Week Range:
$72.89
$212.71
Astrazeneca Plc Stock (AZN) Company Profile
Name
Astrazeneca Plc
Sector
Industry
Phone
-
Address
-
Compare AZN vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
164.49 | 255.82B | 60.48B | 10.40B | 8.05B | 3.3297 |
LLY
Lilly Eli Co
|
1,244.40 | 1.14T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
267.37 | 658.89B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
261.83 | 470.00B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
148.99 | 375.50B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
156.24 | 304.70B | 54.66B | 13.58B | 16.05B | 7.0171 |
Astrazeneca Plc Stock (AZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-27-26 | Initiated | Citigroup | Buy |
| Oct-27-25 | Resumed | Jefferies | Buy |
| Oct-16-25 | Downgrade | Deutsche Bank | Hold → Sell |
| Apr-15-25 | Initiated | Exane BNP Paribas | Outperform |
| Feb-13-25 | Upgrade | UBS | Neutral → Buy |
| Feb-12-25 | Initiated | Morgan Stanley | Overweight |
| Nov-20-24 | Upgrade | UBS | Sell → Neutral |
| Nov-06-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Sep-13-24 | Downgrade | Deutsche Bank | Hold → Sell |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Sell |
| Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-12-23 | Upgrade | UBS | Neutral → Buy |
| Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-29-22 | Upgrade | Argus | Hold → Buy |
| Jun-14-22 | Downgrade | UBS | Buy → Neutral |
| Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
| Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-12-21 | Resumed | JP Morgan | Overweight |
| Apr-12-21 | Downgrade | Argus | Buy → Hold |
| Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Upgrade | UBS | Neutral → Buy |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-30-20 | Upgrade | UBS | Sell → Neutral |
| Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Nov-22-19 | Initiated | SVB Leerink | Outperform |
| Oct-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-02-19 | Downgrade | UBS | Neutral → Sell |
| Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
| Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
| Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
| Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-05-18 | Reiterated | Bernstein | Outperform |
| Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
| Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca Plc Stock (AZN) Latest News
Resilient AstraZeneca stock steadies after recent US gains - Ad-hoc-news.de
AstraZeneca (AZN) Results Check: EPS Prints Above Forecast on the Day; Market Reaction: The Market Price Advances 3.03% at the CloseEarnings Season Outlook - Vinanet
7,500 Shares in Astrazeneca Plc $AZN Bought by Westport Asset Management Inc. - MarketBeat
AstraZeneca PLC : Goldman Sachs reaffirms its Buy rating - marketscreener.com
Is It Too Late to Buy AstraZeneca PLC (AZN) After 3.0% Rally? GF Value Says Undervalued - GuruFocus
AstraZeneca PLC Stock (AZN) Moved Up by 3.40% on Aug 19: What Signal Does It Send? - TradingKey
AstraZeneca Expands Respiratory Pipeline With New China Trial for Chronic Lung Infections - TipRanks
Rumors of AstraZeneca-Bristol-Myers merger fade; focus shifts to each firm's strengths in cancer and immune diseases. - Pluang
AstraZeneca (AZN) CFO’s share award vests at £114.60 a share - Stock Titan
AstraZeneca Vs. Bristol-Myers Squibb: Who’s The Better Bargain For Investors (NYSE:BMY) - Seeking Alpha
Another disappointment: AstraZeneca halts Phase III lung cancer trial for volrustomig - European Biotechnology Magazine
Is AstraZeneca (LSE:AZN) Becoming the Quiet Anchor of a Jittery London Market? - Kalkine Media
Why Is Large Pharmaceutical Pipelines During Broader Market Uncertainty Active In London Today? - Kalkine Media
AstraZeneca CFO Receives First Vesting Under Long-Term Performance Share Plan - TipRanks
REGAstraZeneca PLCDirector/PDMR Shareholding - TradingView
AstraZeneca PLC : Deutsche Bank reiterates its Sell rating - marketscreener.com
AstraZeneca PLC : UBS reiterates its Buy rating - marketscreener.com
BioMarin Pays $275M Upfront for Alesta to Challenge AstraZeneca in Rare Bone Disease - finance.biggo.com
AstraZeneca rises Tuesday, outperforms market - MarketWatch
AstraZeneca maintains Citi 'buy' rating despite mixed pipeline updates - Proactive financial news
AstraZeneca stock edges higher as Q2 2026 growth and EPS gains offset lung cancer trial setback - AD HOC NEWS
Why Is AstraZeneca (LSE:AZN) Anchoring London's Healthcare Trade Today? - Kalkine Media
AstraZeneca’s win in lung cancer; Sandoz inks a China deal - Yahoo Finance
Did AstraZeneca's (LSE:AZN) Lung Cancer Data Just Reset The Blue-Chip Mood Today? - Kalkine Media
AstraZeneca stock rises on lung cancer trial news - AD HOC NEWS
Can AstraZeneca (LSE:AZN) And GSK (LSE:GSK) Turn Regulatory Review Into Durable Progress? - Kalkine Media
Can Shell (LSE:SHEL) And AstraZeneca (LSE:AZN) Turn Capital Allocation Into Durable Progress? - Kalkine Media
Health Care Down on Growth DoubtsHealth Care Roundup - marketscreener.com
AstraZeneca's Portfolio and Pipeline Support Solid Long-Term Growth - Morningstar
These UK Stocks Are Undervalued After Earnings - Morningstar
AstraZeneca Halts Key Lung-Cancer Trial--But Shares Barely Flinch - Yahoo Finance
AstraZeneca Halts Phase III Lung Cancer Trial as Drug Falls Short Against Keytruda - finance.biggo.com
AstraZeneca abandons lung cancer treatment trial in fresh setback for drugs giant - Yahoo Finance UK
AstraZeneca ditches lung cancer treatment trial - Yahoo Finance UK
AstraZeneca scraps Phase 3 trial of new bispecific in lung cancer - BioPharma Dive
UK Shares Start Week Downbeat; AstraZeneca Shares Data from Lung Cancer Trials - marketscreener.com
AstraZeneca stock gains on lung cancer trial news - ad-hoc-news.de
AstraZeneca Reports Mixed Lung Cancer Trial Outcomes From Three Pivotal Studies - Benzinga
Market Wrap: EU chip stocks surge on Anthropic's earnings! AstraZeneca halts trials for lung cancer therapy (17.08.2026) - XTB.com
AstraZeneca (AZN) drug delays progression in first-line HER2 lung cancer - Stock Titan
AstraZeneca axes NSCLC trial after bispecific deemed unlikely to best Keytruda - Clinical Trials Arena
AstraZeneca (NYSE: AZN) halts lung trial after survival goals seen unlikely - Stock Titan
Lung cancer trial success puts AstraZeneca (AZN) drug duo in play - Stock Titan
Plato Investment Management Ltd Takes $5.90 Million Position in Astrazeneca Plc $AZN - MarketBeat
AstraZeneca PLC : JP Morgan remains its Buy rating - marketscreener.com
AstraZeneca halts lung cancer trial in fresh pipeline setback - Proactive financial news
AstraZeneca Ends Phase Three Lung Cancer Drug Trial After Review -- Update - marketscreener.com
FTSE 100 Gains Support From Miners, AstraZeneca And Rolls-Royce - DirectorsTalk Interviews
AstraZeneca PLC (AZN) Stock Analysis: Exploring a 36.59% Potential Upside and Strong Buy Ratings - DirectorsTalk Interviews
AstraZeneca Stops Cancer Drug Trial as Success Seen Unlikely - Bloomberg.com
AstraZeneca Halts Lung Cancer Trial for Volrustomig; Reports Positive Data for Tagrisso Combo, Enhertu - Yahoo Finance UK
Astrazeneca Plc Stock (AZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.95%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):